Obesity Management

The data show a decrease in all-cause mortality for sustained midlife weight loss achieved without surgical or pharmacological interventions.

The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

The nation’s largest PBM is placing Novo Nordisk’s premier weight-loss drug atop its formulary beginning July 1, 2025.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

A conversation with Becky Davis, principal at Charles River Associates, at Asembia’s AXS25 Summit.

Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.

With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Drug Topics to discuss which indications patients typically gravitate toward for the use of GLP-1 medications.

Lydia Newsom, PharmD, discusses how to support patients who are struggling with injection techniques or gastrointestinal side effects of GLP-1s.

Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.

Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.

A conversation with Lydia Newsom, PharmD, clinical associate professor of pharmacy practice at Mercer University College of Pharmacy.